MYC and pancreatic neoplasm: The PPRHs designed demonstrated broad and potent efficacy in MYC-addicted or overexpressing colorectal (SW480), neuroblastoma (SH-Sy5y), breast (MCF-7), prostate (PC-3), and pancreatic cancer cells (AsPc-1).